Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285)

Henan Lingrui Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	772.44	1,499	1,179	801.24	732.32	741.21
Short-Term Investments	184.37	95.63	125.34	140.77	40.08	-
Trading Asset Securities	-	0.21	150.42	280.19	57.23	27.83
Cash & Short-Term Investments	956.81	1,595	1,455	1,222	829.63	769.04
Cash Growth	-25.42%	9.60%	19.05%	47.32%	7.88%	18.53%
Accounts Receivable	825.07	498.99	511.97	431.18	708.6	644.27
Other Receivables	13.64	19.35	21.37	9.58	8.54	18.69
Receivables	838.71	518.34	533.34	440.77	717.13	662.95
Inventory	424.86	467.35	486.41	428.39	331.41	286.68
Prepaid Expenses	-	-	-	-	0.38	0.38
Other Current Assets	41.69	18.51	33.58	39.87	37.98	35.31
Total Current Assets	2,262	2,599	2,508	2,131	1,917	1,754
Property, Plant & Equipment	626.63	647.81	706.76	732.92	730.03	766.04
Long-Term Investments	270.74	1,069	676.63	364.7	349.75	333.89
Goodwill	-	-	-	-	-	0.5
Other Intangible Assets	201.57	202.5	203.65	236.95	235.04	242.05
Long-Term Deferred Tax Assets	212.48	186.92	159.2	116.49	97.79	78.41
Long-Term Deferred Charges	29.58	36.73	51.54	65.53	87.15	98.05
Other Long-Term Assets	1,283	29.98	38.45	145.25	41.45	42.48
Total Assets	4,886	4,772	4,345	3,793	3,458	3,316
Accounts Payable	84.95	57.38	68.02	78.01	78.81	67.66
Accrued Expenses	152.6	1,110	917.79	600.38	528.26	415.85
Short-Term Debt	12.53	199.94	151.15	272.34	166	281
Current Portion of Leases	0.94	1.08	1.22	1.65	-	-
Current Income Taxes Payable	135.68	70.72	55.54	46.9	52.46	47.18
Current Unearned Revenue	39.43	114.48	153.75	79.09	71.73	-
Other Current Liabilities	1,492	346.95	364.47	359.28	169.01	202.1
Total Current Liabilities	1,918	1,900	1,712	1,438	1,066	1,014
Long-Term Leases	7.83	6.96	6.2	7.9	-	-
Long-Term Unearned Revenue	35.04	39.78	38.55	42.78	48.26	55.04
Long-Term Deferred Tax Liabilities	23.12	26.32	29.56	18.18	21.09	26.5
Total Liabilities	1,984	1,973	1,786	1,507	1,136	1,095
Common Stock	567.12	567.14	567.46	567.76	567.81	567.81
Additional Paid-In Capital	337.17	326.23	309.82	272.02	319.63	326.08
Retained Earnings	2,021	1,894	1,664	1,481	1,340	1,185
Treasury Stock	-32.84	-47.4	-67.62	-98.19	-	-
Comprehensive Income & Other	1.64	51	76.74	56.08	84.87	130.73
Total Common Equity	2,894	2,791	2,551	2,279	2,313	2,210
Minority Interest	7.75	7.66	7.55	7.59	9.43	10.56
Shareholders' Equity	2,902	2,799	2,558	2,287	2,322	2,220
Total Liabilities & Equity	4,886	4,772	4,345	3,793	3,458	3,316
Total Debt	21.3	207.99	158.57	281.89	166	281
Net Cash (Debt)	935.51	1,387	1,296	940.31	663.63	488.04
Net Cash Growth	-20.36%	6.96%	37.88%	41.69%	35.98%	31.09%
Net Cash Per Share	1.66	2.45	2.28	1.66	1.17	0.85
Filing Date Shares Outstanding	567.12	563.94	569.61	564.55	562.16	567.81
Total Common Shares Outstanding	567.12	563.94	569.61	564.55	567.81	567.81
Working Capital	344.07	698.77	796.44	693.59	850.28	740.57
Book Value Per Share	5.10	4.95	4.48	4.04	4.07	3.89
Tangible Book Value	2,692	2,589	2,347	2,042	2,078	1,967
Tangible Book Value Per Share	4.75	4.59	4.12	3.62	3.66	3.46
Buildings	-	593.96	595.01	582.83	577.6	577.01
Machinery	-	581.63	581.92	534.7	511.65	492.22
Construction In Progress	-	2.88	1.92	24.78	2.78	9.03

Source: S&P Capital IQ. Standard template. Financial Sources.